Patents by Inventor Alberto Hayek
Alberto Hayek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090155218Abstract: The present invention relates to methods, compositions, and kits for maintenance of the undifferentiated state and/or pluripotency in stem cells, including embryonic stem (ES) cells. It also relates to stem cells that have been maintained in an undifferentiated state. The present invention provides these aspects using culture medium enriched with a TGF? family member protein, an FGF family member protein, and/or nicotinamide, without using fibroblast feeder layers, conditioned media, or leukemia inhibitory factor.Type: ApplicationFiled: March 9, 2005Publication date: June 18, 2009Inventors: Alberto Hayek, Gillian Beattie, Ana Lopez
-
Publication number: 20030228287Abstract: The present invention provides a method of culturing cells on a matrix. The present invention includes islet cells cultured in a 3-D configuration in the presence of a fibrin matrix support. Induction of &bgr;-cell proliferation with HGF/SF is also provided.Type: ApplicationFiled: October 18, 2002Publication date: December 11, 2003Applicant: Regents of the University of CaliforniaInventors: Gillian M. Beattie, Alberto Hayek, Anthony Montgomery
-
Publication number: 20030202967Abstract: This invention relates to cell lines, particularly mammalian cell lines, established by transforming the cells with vectors, preferably retroviral vectors, containing two or more oncogenes under the control of one or more inducible promoters and/or genetic elements. Also within the scope of the invention are human cell lines with extended in vitro lifespan, transformed by vectors containing one or more oncogenes under the control of one or more, preferably exogenous, inducible promoters and/or genetic elements. The vectors may additionally contain gene(s) encoding for desired gene product(s). Also disclosed are insulin producing human pancreatic cell lines useful for transplantation into human diabetic patients.Type: ApplicationFiled: March 27, 2003Publication date: October 30, 2003Applicants: The Regents of the University of California, Whittier Institute for Diabetes and EndocrinologyInventors: Fred Levine, Sijian Wang, Gillian M. Beattie, Alberto Hayek
-
Publication number: 20020037276Abstract: This invention pertains to the discovery that inhibition of phosphatidylinositol 3-kinase (PI3K) in human fetal undifferentiated cells induces morphological and functional endocrine differentiation. This is associated with an increase in MRNA levels of insulin, glucagon, and somatostatin, as well as an increase in the insulin protein content and secretion response to secretagogues. Blockade of PI3K also increases the proportion of pluripotent precursor cells coexpressing multiple hormones and the total number of terminally differentiated cells originating from these precursor cells. In one embodiment, this invention thus rpov9des methods for endocrine differentiation in cultured cells.Type: ApplicationFiled: May 26, 1999Publication date: March 28, 2002Inventors: ANDRZEJ PTASZNIK, ALBERTO HAYEK, GILLIAN M. BEATTIE
-
Patent number: 6110743Abstract: This invention relates to cell lines, particularly mammalian cell lines, established by transforming the cells with vectors, preferably retroviral vectors, containing two or more oncogenes under the control of one or more inducible promoters and/or genetic elements. Also within the scope of the invention are human cell lines with extended in vitro lifespan, transformed by vectors containing one or more oncogenes under the control of one or more, preferably exogenous, inducible promoters and/or genetic elements. The vectors may additionally contain gene(s) encoding for desired gene product(s). Also disclosed are insulin producing human pancreatic cell lines useful for transplantation into human diabetic patients.Type: GrantFiled: June 26, 1997Date of Patent: August 29, 2000Assignees: The Regents of the University of California, Whittier Institute for Diabetes and EndocrinologyInventors: Fred Levine, Sijian Wang, Gillian M. Beattie, Alberto Hayek
-
Patent number: 5888705Abstract: A method of inducing the proliferation and/or differentiation of human adult pancreatic cells entails contacting primary cultures of such cells with Hepatocyte Growth Factor/Scatter Factor (HGF/SF), thereby inducing a proliferation of .beta.-epithelial cells, an increase in the number of .beta.-epithelial cells which form islet-like cell clusters, and an increase in insulin production per cell. The method is improved by culturing the cells on an extracellular matrix such as 804G in the presence of HGF/SF, and is further improved by reaggregating thus-treated cells and contacting said cells with an insulin gene upregulating agent such as a poly(ADP-ribose) synthetase inhibitor such as a nicotinamide or benzamide. The method provides increased numbers of functional islet-like cell clusters for transplantation.Type: GrantFiled: April 14, 1997Date of Patent: March 30, 1999Assignees: The United States of America as represented by the Department of Health and Human Services, The Whittier Institute for Diabetes and EndocrinologyInventors: Jeffrey Rubin, Alberto Hayek, Gillian Marguerite Beattie, Timo Pyry Juhani Otonkoski, Vito Quaranta
-
Patent number: 5874306Abstract: Human pancreatic endocrine cells are proliferated without loss of hormone function in a culture medium containing extracellular matrix from bladder carcinoma cell lines in the substantial absence of hepatocyte growth factor/scatter factor. Proliferation is preferably carried out in the substantial absence of any peptide growth factors and nicotinamide. The cells may be proliferated in a monolayer on a solid substrate. Islets and islet-like cell clusters are proliferated without loss of insulin-secreting function by incubation in a medium containing extracellular matrix from a human bladder carcinoma cell line, preferably cell line ATCC HTB-9.Type: GrantFiled: December 12, 1996Date of Patent: February 23, 1999Assignee: The Regents of the University of CaliforniaInventors: Gillian M. Beattie, Alberto Hayek
-
Patent number: 5827741Abstract: The combination of trehalose and dimethyl sulfoxide is an unusually effective cryoprotectant for islets and islet-like cell clusters, as well as platelets. Islets and ICCs, when cooled through the thermotropic phase transition in the presence of this combination of treatment agents and then returned to physiologic temperature, retain their functionality. Likewise, platelets can be similarly cooled and warmed without undergoing premature activation. In general, trehalose can be incorporated into eukaryotic cells in general by suspending the cells in a trehalose solution and either cooling or warming the solution through the thermotropic transition of the cells.Type: GrantFiled: November 19, 1996Date of Patent: October 27, 1998Assignee: The Regents of the University of CaliforniaInventors: Gillian M. Beattie, John H. Crowe, Fern Tablin, Alberto Hayek
-
Patent number: 5723333Abstract: This invention relates to cell lines, particularly mammalian cell lines, established by transforming the cells with vectors, preferably retroviral vectors, containing two or more oncogenes under the control of one or more inducible promoters and/or genetic elements. Also within the scope of the invention are human cell lines with extended in vitro lifespan, transformed by vectors containing one or more oncogenes under the control of one or more, preferably exogenous, inducible promoters and/or genetic elements. The vectors may additionally contain gene(s) encoding for desired gene product(s). Also disclosed are insulin producing human pancreatic cell lines useful for transplantation into human diabetic patients.Type: GrantFiled: July 31, 1995Date of Patent: March 3, 1998Assignee: Regents of The University of CaliforniaInventors: Fred Levine, Sijian Wang, Gillian M. Beattie, Alberto Hayek
-
Patent number: 5587309Abstract: A method of inducing the proliferation and/or differentiation of human fetal pancreatic cells entails contacting such cells in primary culture with Hepatocyte Growth Factor/Scatter Factor, thereby inducing a proliferation of .beta.-epithelial cells, an increase in the number of .beta.-epithelial cells which form islet-like cell clusters, and an increase in insulin production per cell. The method provides increased numbers of functional islet-like cell clusters for transplantation, for example, into Type 1 diabetic patients. The method can be scaled up so as to provide clinically useful numbers of cells for transplantation.Type: GrantFiled: April 29, 1994Date of Patent: December 24, 1996Assignees: The United States of America as represented by the Department of Health and Human Services, Whittler Institute for Diabetes and EndocrinologyInventors: Jeffrey Rubin, Alberto Hayek, Gillian M. Beattie, Timo P. J. Otonkoski
-
Patent number: 5116753Abstract: The addition of basic FGF-saporin mitotoxins selectively elminates fibroblastoids from human islets in culture and increases the ability of such islets to release insulin under basal and stimulated conditions. When such islets are attached to an extracellular matrix, in particular BCEM, the proliferation of islet cells is favored, and the ability of islets cultured in such manner to release insulin is further increased. Moreover, supplementation of the culture media with high glucose or insulin further improves the functioning of the human islets, resulting in augmented insulin release. Combinations of such procedures offer a novel approach towards the establishment of viable human islet cell monolayers for clinical and laboratory research.Type: GrantFiled: July 30, 1991Date of Patent: May 26, 1992Assignees: The Salk Institute for Biological Studies, The Whittier Institute for Diabetes & EndocrinologyInventors: Gillian M. Beattie, Douglas A. Lappi, J. Andrew Baird, Alberto Hayek